Document is current
Any future updates will be listed below
-
Authors
Kim, Yunna https://orcid.org/0000-0003-2286-1242
Choi, Yujin https://orcid.org/0000-0001-5257-2340
Lee, Mi Young https://orcid.org/0000-0002-3308-340X
Cho, Seung-Hun https://orcid.org/0000-0002-0627-768X
Jung, In Chul https://orcid.org/0000-0001-7245-4990
Kang, Dong-Hoon
Yang, Changsop https://orcid.org/0000-0003-1277-3329
-
Funding
Funding for this research was provided by:
Korea Health Industry Development Institute (HI21C2520, HI21C2520, HI21C2520, HI21C2520, HI21C2520, HI21C2520, HI21C2520)
- License Information
-
More Information
Article History
Received: 13 January 2023
Accepted: 7 March 2023
First Online: 12 April 2023
Declarations
:
: This study has been approved by the institutional review board of the Kyung Hee University Korean Medicine Hospital (approval number: KOMCIRB2022-05–007-001) and Daejeon Korean Medicine Hospital of Daejeon University (approval number: DJDSKH-22-DR-10).Written informed consent will be obtained from all participants before the screening process. The principal investigator and sub-investigators who are Korean medicine doctors in the hospital and delegated by the principal investigators will provide all information pertaining to the clinical study and obtain informed consent from participants. The informed consent and description of the study approved by the IRB will be used. Sufficient time and opportunity for participants to ask questions about the details of the clinical study and to decide whether to participate will be provided.
: Not applicable.
: MYL and CY are holding a patent for BTS extract on improving depressive and anxiety disorders. The other authors declare that there is no conflict of interest.
